Ads
related to: meningococcal meningitis structure and drug resistance treatment recommendations- FAQs
Discover FAQs About Meningitis B &
Be Prepared With More Facts.
- Meningitis B
Learn More About The Signs &
Symptoms Of Meningitis B.
- Safety Information
Find Important Safety Information
Online Now By Visiting Here.
- Vaccine Locator Tool
Locate A Vaccine Provider Near You
With The Vaccine Locator Tool.
- FAQs
Search results
Results From The WOW.Com Content Network
Meningococcal meningitis is a form of bacterial meningitis. Meningitis is a disease caused by inflammation and irritation of the meninges , the membranes surrounding the brain and spinal cord. In meningococcal meningitis this is caused by the bacteria invading the cerebrospinal fluid and circulating through the central nervous system .
In June 2012, the U.S. Food and Drug Administration (FDA) approved a combination vaccine against two types of meningococcal diseases and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix , was designed to prevent disease caused by Neisseria meningitidis serogroups C and Y, and Haemophilus influenzae type b (Hib).
On February 26, 2015, ACIP voted to deliver a Category A recommendation for administering MenB vaccines to persons older than 10 years who were at higher risk of meningococcal disease. On June 24, 2015, ACIP heard the arguments for recommending Pfizer and Novartis's serogroup B meningococcal vaccines for everyone in the 16-22 age group.
In cases of meningococcal meningitis, preventative treatment in close contacts with antibiotics (e.g. rifampicin, ciprofloxacin or ceftriaxone) can reduce their risk of contracting the condition, but does not protect against future infections. [48] [69] Resistance to rifampicin has been noted to increase after use, which has caused some to ...
The first-of-its-kind shot addresses the five most common causes of meningococcal disease, Pfizer says. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines .
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [9] [10] The vaccines are between 85 and 100% effective for at least two years. [9]
N. meningitidis (also called the meningococcus) is one of the most common causes of bacterial meningitis and the causative agent of meningococcal septicaemia. The immune system's neutrophils are restricted in function due to the ability of Neisseria to evade opsonization by antibodies, and to replicate within neutrophils despite phagocytosis.